General Information of the Ferroptosis Regulator (ID: REG10180)
Regulator Name Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)
Synonyms
MMAC1, TEP1; Mutated in multiple advanced cancers 1; Phosphatase and tensin homolog
    Click to Show/Hide
Gene Name PTEN
Gene ID 5728
Regulator Type Protein coding
Uniprot ID P60484
Sequence
MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSK
HKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVA
AIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSY
LLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMY
FEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEI
DSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEAS
SSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV

    Click to Show/Hide
Family PTEN phosphatase protein family
Function
Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. Tumor suppressor, the lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with MAGI2 to suppress AKT1 activation. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Required for growth factor-induced epithelial cell migration; growth factor stimulation induces PTEN phosphorylation which changes its binding preference from the p85 regulatory subunit of the PI3K kinase complex to DLC1 and results in translocation of the PTEN-DLC1 complex to the posterior of migrating cells to promote RHOA activation. Meanwhile, TNS3 switches binding preference from DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge of migrating cells to activate RAC1 activation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Involved in the regulation of synaptic function in excitatory hippocampal synapses. Recruited to the postsynaptic membrane upon NMDA receptor activation, is required for the modulation of synaptic activity during plasticity. Enhancement of lipid phosphatase activity is able to drive depression of AMPA receptor-mediated synaptic responses, activity required for NMDA receptor-dependent long-term depression (LTD). May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability.

    Click to Show/Hide
HGNC ID
HGNC:9588
KEGG ID hsa:5728
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
PTEN can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Nuclear factor erythroid 2-related factor 2 (NFE2L2) [Suppressor; Marker]
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Breast cancer ICD-11: 2C60
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Ubiquitin mediated proteolysis hsa04120
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model
HCC1419 cells Breast ductal carcinoma Homo sapiens CVCL_1251
HCC1395 cells Breast ductal carcinoma Homo sapiens CVCL_1249
NCI-H226 cells Pleural epithelioid mesothelioma Homo sapiens CVCL_1544
NCI-H446 cells Lung small cell carcinoma Homo sapiens CVCL_1562
ZR-75-1 cells Invasive breast carcinoma Homo sapiens CVCL_0588
HCC1937 cells Breast ductal carcinoma Homo sapiens CVCL_0290
HCC1187 cells Breast ductal carcinoma Homo sapiens CVCL_1247
HCC1806 cells Breast squamous cell carcinoma Homo sapiens CVCL_1258
BT-549 cells Invasive breast carcinoma Homo sapiens CVCL_1092
NCI-H520 cells Lung squamous cell carcinoma Homo sapiens CVCL_1566
mEFs (Mouse embryonic fibroblasts)
In Vivo Model
A cross between 12 week old, B6.129S4 Ptenfl/fl mice obtained from Jackson Laboratory was set up and 14 days later both male and female embryos were harvested from the pregnant females. Highly vascularized sections of the embryos were removed - head, extremities, and liver. The remainder was minced via a scalpel and resuspended in 0.25% trypsin using a pipet. The cells were then incubated for 10 min in an incubator at 37 with 5% CO2 before being further resuspended into single cell suspension. The cells were then spun down at 1500 RPM for 5 min to remove the trypsin, after which they were resuspended in 10 mL of fresh media and transferred to a 10 cm dish.

    Click to Show/Hide
Response regulation Loss of PTEN activates AKT kinase to inhibit GSK3, increasing NF-E2 p45-related factor 2 (NRF2) along with transcription of one of its known target genes encoding xCT in breast cancers.
Breast cancer [ICD-11: 2C60]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) Protein coding
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Ubiquitin mediated proteolysis hsa04120
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model
HCC1419 cells Breast ductal carcinoma Homo sapiens CVCL_1251
HCC1395 cells Breast ductal carcinoma Homo sapiens CVCL_1249
NCI-H226 cells Pleural epithelioid mesothelioma Homo sapiens CVCL_1544
NCI-H446 cells Lung small cell carcinoma Homo sapiens CVCL_1562
ZR-75-1 cells Invasive breast carcinoma Homo sapiens CVCL_0588
HCC1937 cells Breast ductal carcinoma Homo sapiens CVCL_0290
HCC1187 cells Breast ductal carcinoma Homo sapiens CVCL_1247
HCC1806 cells Breast squamous cell carcinoma Homo sapiens CVCL_1258
BT-549 cells Invasive breast carcinoma Homo sapiens CVCL_1092
NCI-H520 cells Lung squamous cell carcinoma Homo sapiens CVCL_1566
mEFs (Mouse embryonic fibroblasts)
In Vivo Model
A cross between 12 week old, B6.129S4 Ptenfl/fl mice obtained from Jackson Laboratory was set up and 14 days later both male and female embryos were harvested from the pregnant females. Highly vascularized sections of the embryos were removed - head, extremities, and liver. The remainder was minced via a scalpel and resuspended in 0.25% trypsin using a pipet. The cells were then incubated for 10 min in an incubator at 37 with 5% CO2 before being further resuspended into single cell suspension. The cells were then spun down at 1500 RPM for 5 min to remove the trypsin, after which they were resuspended in 10 mL of fresh media and transferred to a 10 cm dish.

    Click to Show/Hide
Response regulation Loss of PTEN activates AKT kinase to inhibit GSK3, increasing NF-E2 p45-related factor 2 (NRF2) along with transcription of one of its known target genes encoding xCT in breast cancers.
References
Ref 1 AKT activation because of PTEN loss upregulates xCT via GSK3/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells. Cell Rep. 2023 May 30;42(5):112536. doi: 10.1016/j.celrep.2023.112536. Epub 2023 May 20.